TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18560227

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: amodiaquine-sulfalene-pyrimethamine
Number of subjects: 42
Study: 16332471

Group type: EXPERIMENTAL
Intervention: Training of Child Health Doctors (CHDs) in a structured method to identify psychosocial problems
Number of subjects: 6375

Group type: COMPARATOR
Intervention: Control condition (no training)
Number of subjects: 6375
Study: 12564609

Group type: EXPERIMENTAL
Intervention: Sibenadet (500 microg three times daily) plus placebo (twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily) plus placebo (three times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (twice daily) plus a second placebo (three times daily)
Number of subjects: 0
Study: 11236240

Group type: EXPERIMENTAL
Intervention: Diabetic patients with type 2 diabetes
Number of subjects: 40
Study: 8628600

Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB) therapy, 10 mg/kg IV followed by 100 mg orally daily until delivery.
Number of subjects: 110
Study: 1458895

Group type: EXPERIMENTAL
Intervention: Mechanical dilator (Lamicel; n = 17)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Prostaglandin (gemeprost; n = 17)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Antiprogesterone (Mifepristone; n = 15)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo control (n = 15)
Number of subjects: 64
Study: 6142007

Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30930211

Group type: EXPERIMENTAL
Intervention: Pulmonary Recruitment Maneuver (PRM) with maximal inspiratory pressure of 30 cm H2O
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 31039878

Group type: EXPERIMENTAL
Intervention: GO/Cu₂O composite
Number of subjects: 0
Study: 27943408

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (non-diabetics)
Number of subjects: 99
Study: 25196976

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (doses ranging from 500 to 3000 mg)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Number of subjects: 376
Study: 22451196

Group type: COMPARATOR
Intervention: Haloperidol (3 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aripiprazole (10 mg)
Number of subjects: 20
Study: 21173169

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) in women
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) in men
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Former cigarette smoking
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Current cigarette smoking
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Smoking duration
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (per 10 g ethanol/d)
Number of subjects: 120852
Study: 19292213

Group type: EXPERIMENTAL
Intervention: Congenital group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Acquired group
Number of subjects: 88
Study: 16485700

Group type: EXPERIMENTAL
Intervention: Leucocyte-depleting (LD) filter
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control standard arterial line filter
Number of subjects: 60
Study: 14585882

Group type: EXPERIMENTAL
Intervention: Clinical evaluation of IUD position immediately after insertion
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Clinical evaluation of IUD position at follow-up (6 weeks after insertion)
Number of subjects: 195
Study: 11124286

Group type: EXPERIMENTAL
Intervention: Low-dose 5-fluorouracil (3 subconjunctival injections of 5 mg each over 11 postoperative days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trabeculectomy without 5-fluorouracil
Number of subjects: 40
Study: 9020998

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (5 micrograms kg‐1 min‐1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1364168

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cyproheptadine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ketotifen
Number of subjects: 7

Group type: COMPARATOR
Intervention: All antihistamines
Number of subjects: 7
Study: 3974097

Group type: EXPERIMENTAL
Intervention: Oral albuterol, 4 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral metaproterenol sulfate, 20 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral terbutaline sulfate, 5 mg
Number of subjects: 20
Study: 30509278

Group type: EXPERIMENTAL
Intervention: CAP definition patterns (8 patterns identified)
Number of subjects: 319
Study: 26406192

Group type: EXPERIMENTAL
Intervention: Tetrax group (TG) - 15 minutes exercise session 3 times weekly for 4 weeks
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Electrostimulation group (EG) - 40 minutes electrostimulation of postural muscles 3 times weekly for 4 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group - 6-week balance exercises
Number of subjects: 57
Study: 26420180

Group type: EXPERIMENTAL
Intervention: 1000 μg of vitamin B‐12
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 g fish oil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1000 μg vitamin B‐12 and 2 g fish oil
Number of subjects: 30
Study: 23423495

Group type: EXPERIMENTAL
Intervention: Feedback (GIH A)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No feedback (GIH B, control group)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study: 21906811

Group type: EXPERIMENTAL
Intervention: TB-403 (0.3 to 5.0 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18362604

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline 100 mm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine‐prilocaine cream (positive control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline (all concentrations)
Number of subjects: 0
Study: 16980157

Group type: EXPERIMENTAL
Intervention: bupivacaine-diclofenac
Number of subjects: 90

Group type: COMPARATOR
Intervention: bupivacaine-placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: placebo-diclofenac
Number of subjects: 90
Study: 12356389

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day) + L-arginine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10332518

Group type: EXPERIMENTAL
Intervention: Microsoft Natural Keyboard (kb3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Apple Adjustable Keyboard (kb1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7867175

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches applied for 12 hours daily for 30 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1959368

Group type: EXPERIMENTAL
Intervention: sucralfate (1 g every 6 hrs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ranitidine (50 mg every 6 hrs)
Number of subjects: 60
Study: 7124567

Group type: EXPERIMENTAL
Intervention: High doses of vitamin B6 and magnesium
Number of subjects: 44
Study: 30393015

Group type: EXPERIMENTAL
Intervention: e‐cig
Number of subjects: 263

Group type: COMPARATOR
Intervention: cig‐sub
Number of subjects: 263
Study: 28356136

Group type: EXPERIMENTAL
Intervention: Rapid intermittent bolus with hypertonic saline
Number of subjects: 178

Group type: COMPARATOR
Intervention: Slow continuous infusion with hypertonic saline
Number of subjects: 178
Study: 27108405

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneous injections, 6 doses total, starting on day one and every 6 months until 30 months)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections, 6 doses total, starting on day one and every 6 months until 30 months)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 110
Study: 24074637

Group type: EXPERIMENTAL
Intervention: Sodium benzoate (250-750 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22147202

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 18973142

Group type: EXPERIMENTAL
Intervention: Detailed explanatory leaflet about urodynamic consultation
Number of subjects: 129

Group type: COMPARATOR
Intervention: No detailed explanatory leaflet (control group)
Number of subjects: 129
Study: 18022231

Group type: EXPERIMENTAL
Intervention: diacetylmorphine
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 8
Study: 15676176

Group type: COMPARATOR
Intervention: Obesity assessed by BMI (overweight and obese groups)
Number of subjects: 6676

Group type: COMPARATOR
Intervention: WHR in the upper quartile
Number of subjects: 6676

Group type: COMPARATOR
Intervention: Increasing WHR in women
Number of subjects: 6676
Study: 12486207

Group type: EXPERIMENTAL
Intervention: Ingested IFN‐alpha in type 1 diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ingested IFN‐alpha in rheumatoid arthritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ingested IFN‐alpha in multiple sclerosis (phase I trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ingested IFN‐alpha (10,000 IU) in multiple sclerosis (phase II trial)
Number of subjects: 0
Study: 9935129

Group type: EXPERIMENTAL
Intervention: Intermittent dosing of progestin (5 mg twice per week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continuous dosing of progestin (2.5 mg daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both regimens (intermittent and continuous dosing)
Number of subjects: 100
Study: 8527617

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 276

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 276
Study: 2149829

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:200,000 epinephrine (Group L)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1000 micrograms alfentanil (Group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200 micrograms fentanyl (Group F)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 60 micrograms sufentanil (Group S)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 60 micrograms sufentanil without test dose (Group S‐)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Epidural narcotics (alfentanil, fentanyl, sufentanil)
Number of subjects: 100
Study: 6987026

Group type: EXPERIMENTAL
Intervention: Fluproquazone (75 to 200 mg)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Fluproquazone (100 to 150 mg)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Aspirin (1,000 mg)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study: 31707286

Group type: EXPERIMENTAL
Intervention: 10 μg of vitamin D supplementation
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 25 μg of vitamin D supplementation
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo (2 μg of vitamin D)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 10 μg and 25 μg of vitamin D supplementation
Number of subjects: 170
Study: 31371396

Group type: EXPERIMENTAL
Intervention: Ludwig staging system
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ishak staging system
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Histological parameters (IFH and sinusoidal fibrosis)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sinusoidal fibrosis
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Liver biopsy
Number of subjects: 106
Study: 26175020

Group type: EXPERIMENTAL
Intervention: Early mobilisation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plaster immobilisation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 25872789

Group type: EXPERIMENTAL
Intervention: 12-week individualised aerobic exercise programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: 12-week waiting control group
Number of subjects: 60
Study: 23498360

Group type: EXPERIMENTAL
Intervention: Automated gaming technology training and audit tool
Number of subjects: 0
Study: 21376910

Group type: EXPERIMENTAL
Intervention: Use of Restraint Fitting Stations
Number of subjects: 0

Group type: COMPARATOR
Intervention: No use of Restraint Fitting Stations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Length of restraint ownership
Number of subjects: 0
Study: 19681774

Group type: COMPARATOR
Intervention: Single stimulation (Group S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Double stimulation (Group D)
Number of subjects: 60
Study: 17365952

Group type: EXPERIMENTAL
Intervention: Sea level (SL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1,500 m
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3,000 m
Number of subjects: 10
Study: 14624940

Group type: EXPERIMENTAL
Intervention: High barley diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 10
Study: 11004042

Group type: EXPERIMENTAL
Intervention: Ciaglia Blue Rhino (CBR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Basic Ciaglia technique of percutaneous dilational tracheostomy (PDT)
Number of subjects: 50
Study: 8971536

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil 5% (5‐FU) topical application plus Interferon alpha‐2a (IFA alpha‐2a) (high dose)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: CO2 laser vaporization plus 5‐FU plus Interferon alpha‐2a (IFA alpha‐2a) (high dose)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: CO2 laser vaporization plus 5‐FU
Number of subjects: 505
Study: 1486776

Group type: EXPERIMENTAL
Intervention: Emcredil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study: 6365156

Group type: EXPERIMENTAL
Intervention: 200 mg/day of danazol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher dosages of danazol
Number of subjects: 0
Study: 3086597

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) followed by carmofur (HCFU) for more than three months (arm B)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Mitomycin C (MMC) alone (arm A)
Number of subjects: 173
Study: 28864036

Group type: EXPERIMENTAL
Intervention: HR-targeted aerobic exercise training
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no HR-targeted training)
Number of subjects: 126
Study: 28295907

Group type: EXPERIMENTAL
Intervention: Omission of HF medication for 48 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular medication
Number of subjects: 20
Study: 25764513

Group type: EXPERIMENTAL
Intervention: Two doses of oral cholera vaccine at 14 day interval
Number of subjects: 356

Group type: COMPARATOR
Intervention: Two doses of oral cholera vaccine at 28 day interval
Number of subjects: 356
Study: 23724913

Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg orally twice daily)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m² or docetaxel 75 mg/m² every 3 weeks)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 347

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 347
Study: 20578380

Group type: EXPERIMENTAL
Intervention: Isolated herbal moxibustion on Shenque (CV 8)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Western medication (analgesic)
Number of subjects: 102
Study: 18400583

Group type: EXPERIMENTAL
Intervention: Single intrauterine insemination
Number of subjects: 100

Group type: COMPARATOR
Intervention: Double intrauterine insemination
Number of subjects: 100
Study: 16618043

Group type: EXPERIMENTAL
Intervention: Trigger point acupuncture
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 26
Study: 14762984

Group type: EXPERIMENTAL
Intervention: Complementary medicine intervention (specifics not provided)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Physician MD as complementary medicine practitioner
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Teaching complementary medicine in medical and nursing schools
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Knowledge about adverse reactions to complementary therapies
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Legalizing complementary medicine
Number of subjects: 429
Study: 11000645

Group type: EXPERIMENTAL
Intervention: Paroxetine (n = 137), starting at 10 mg/d and titrated to a maximum of 40 mg/d
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Problem-solving treatment-primary care (PST-PC; n = 138)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Paroxetine (for dysthymia patients)
Number of subjects: 415

Group type: COMPARATOR
Intervention: PST-PC (for dysthymia patients)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Paroxetine (for minor depression patients)
Number of subjects: 415

Group type: COMPARATOR
Intervention: PST-PC (for minor depression patients)
Number of subjects: 415
Study: 8792922

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg once daily (n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 60
Study: 1734739

Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 16
Study: 12267336

Group type: EXPERIMENTAL
Intervention: 0.2gm WCMAS
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 0.4gm WCMAS
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 0.6gm WCMAS
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Serum hCG and progesterone levels
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Follow-up of 48 cases
Number of subjects: 74
Study: 31090750

Group type: EXPERIMENTAL
Intervention: Intraoral digital impression (fully digital group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional impression and scan model (conventional group)
Number of subjects: 20
Study: 29096998

Group type: EXPERIMENTAL
Intervention: rs3750846 SNP at the ARMS2/HTRA1 locus
Number of subjects: 1776

Group type: EXPERIMENTAL
Intervention: rs10922109 SNP at the CFH locus
Number of subjects: 1776

Group type: EXPERIMENTAL
Intervention: rs570618 SNP at the CFH locus
Number of subjects: 1776
Study: 27068252

Group type: EXPERIMENTAL
Intervention: Cellphone Assisted Remote Observation of Medication Adherence (CAROMA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active study medication
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25178925

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 48
Study: 22488460

Group type: EXPERIMENTAL
Intervention: Model 1 (usual outcall protocol of an academic hospital genetic risk program)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Model 2 (screening and referral procedures of a statewide toll-free phone line)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Model 2 (after 2 months follow-up)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Model 1 (after 2 months follow-up)
Number of subjects: 38
Study: 20102444

Group type: EXPERIMENTAL
Intervention: Local estrogen cream
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Local estrogen and testosterone cream
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nonhormonal lubricant KY gel (control)
Number of subjects: 75
Study: 17914966

Group type: EXPERIMENTAL
Intervention: Lactoferrin monotherapy for 8 weeks followed by lactoferrin, interferon, and ribavirin for 24 weeks
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Lactoferrin, interferon, and ribavirin combination therapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Interferon and ribavirin for 24 weeks
Number of subjects: 111
Study: 15618068

Group type: EXPERIMENTAL
Intervention: Prior PCI
Number of subjects: 24166

Group type: COMPARATOR
Intervention: No prior PCI
Number of subjects: 24166
Study: 12355332

Group type: EXPERIMENTAL
Intervention: Ephedra-caffeine (Xenadrine(TM); XEN)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 27
Study: 10671656

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 8853250

Group type: EXPERIMENTAL
Intervention: Weight loss (energy-restricted diet, physical exercise, intragastric balloon)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Weight loss (58.4 kg) of those remaining or becoming acid refluxers
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Chronic gastric distension (500 ml balloon)
Number of subjects: 17
Study: 1507022

Group type: EXPERIMENTAL
Intervention: Statistical procedures for analysis of data from periodontal research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase II periodontal disease clinical trial
Number of subjects: 0
Study: 2857088

Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31362548

Group type: EXPERIMENTAL
Intervention: K-wire fixation
Number of subjects: 448

Group type: COMPARATOR
Intervention: Locking-plate fixation
Number of subjects: 448
Study: 30021340

Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 27149465

Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) - 1 session per week for 3 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) - 1 single session
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham rESWT - 1 session per week for 3 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) - 3 sessions
Number of subjects: 60
Study: 24806009

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction and tendon interposition
Number of subjects: 43

Group type: COMPARATOR
Intervention: Arthrodesis with plate and screws
Number of subjects: 43